



## See 1 citation found by title matching your search:

*Histopathology*. 2015 Jun;66(7):991-1002. doi: 10.1111/his.12613. Epub 2015 Jan 13.

## PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.

He HL<sup>1,2</sup>, Lee YE<sup>3</sup>, Shiu YL<sup>2</sup>, Lee SW<sup>4</sup>, Lin LC<sup>5</sup>, Chen TJ<sup>6</sup>, Wu TF<sup>7</sup>, Li CF<sup>6,7,8,9</sup>.

### Author information

#### Abstract

**AIMS:** The aim of this study was to investigate the prognostic impact of group IIA phospholipase A2 (**PLA2G2A**) expression and its role in predicting the **response to neoadjuvant concurrent chemoradiotherapy (CCRT) in rectal cancer**.

**METHODS AND RESULTS:** Through analysing a public transcriptome of **rectal cancers**, the **PLA2G2A** gene was identified as a significant predictor for **CCRT response**. We validated the expression of **PLA2G2A** using immunohistochemistry in the pretreatment tumour specimens from **172 patients with rectal cancer**. The results were correlated with clinicopathological features, tumour regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of **PLA2G2A** was **associated** with advanced pretreatment tumour status (P = 0.001), advanced pretreatment nodal status (P = 0.010), advanced post-treatment tumour status (P = 0.002) and lower tumour regression grade (P = 0.006). Furthermore, **PLA2G2A** expression was correlated negatively with gamma H2A histone family, member X ( $\gamma$ -H2AX) expression (P < 0.001, r = -0.580). More importantly, high expression of **PLA2G2A** emerged as an adverse prognostic factor for OS (P = 0.0190), DFS (P < 0.0001) and LRFS (P < 0.0001). In multivariate analysis, it remained independently prognostic for shorter DFS (P = 0.014) and LRFS (P = 0.012).

**CONCLUSIONS:** High expression of **PLA2G2A** was **associated with poor therapeutic response and worse survival in patients with rectal cancer receiving neoadjuvant CCRT**, justifying **PLA2G2A** as an important marker to predict **CCRT response and outcome**.

© 2014 John Wiley & Sons Ltd.

**KEYWORDS:** CCRT; **PLA2G2A**; chemoradiotherapy; rectal cancer

PMID: 25393083 DOI: [10.1111/his.12613](https://doi.org/10.1111/his.12613)

[PubMed - in process]

Publication Types



LinkOut - more resources

